texas oncology more breakthroughs. more victories
Some of our cancer centers may have important notifications found on the location page. View More Important Notifications x

Tri Cao Le, M.D.

Tri Cao Le, M.D. Photo

Provider Type: Physician

Specialties:
Board Certifications:
  • Internal Medicine

Downloads

Education

  • Fellowship in Hematology and Medical Oncology 
    The University of Texas Southwestern Medical Center, Dallas, TX
  • Residency in Internal Medicine 
    The University of Texas Southwestern Medical Center, Dallas, TX
  • Medical Doctorate 
    Duke University, Durham, NC

Accolades & Memberships

Dr. Le is a member of the American Society of Hematology and the American Society of Clinical Oncology. He has authored and co-authored several publications in peer-reviewed journals and presented his work at numerous local and national conferences. His clinical excellence, commitment to teaching and mentorship, and leadership were recognized when he was selected as a chief resident and later, chief fellow at his training institutions.

  • The University of Texas Southwestern Medical Center, Chief Fellow, Dallas, TX (2020 – 2021)
  • Texas Society of Clinical Oncology Annual Conference, Outstanding Fellow Abstract (2019)
  • The University of Texas Southwestern Medical Center, Medical Student Clerkship Teaching Award for Faculty, Dallas, TX (2018)
  • Travel Grant for PRIME Oncology Young Investigator Forum (2018)
  • The University of Texas Southwestern Medical Center, Chief Resident, Dallas, TX (2017 – 2018)

Publications

  •  Covid-19 Associated Coagulopathy

    Feature Article in the University of Texas Southwestern Covid-19 Action Newsletter, 2020

  • Checkpoint Inhibitor Pneumonitis: Too Clinically Serious For Benefit?

    Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer, 2019

  • Improved Survival Outcomes for Kidney Cancer Patients with Brain Metastases

    Clinical Genitourinary Cancer, 2019

  • Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?

    Cancers, 2019

  • QTc Interval-Prolonging Medications Among Patients with Lung Cancer: Implications for Clinical Trial Eligibility and Clinical Care

    Clinical Lung Cancer, 2019

Show all Publications
  • Prevalence and Significance of Drug-Drug Interactions Among Patients With Lung Cancer

    Proceedings of the American Association for Cancer Research Annual Meeting 2019, 2019

  • Real World Outcomes of Nivolumab and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)

    American Society of Clinical Oncology, 2018

  • Improved Survival Rates in Kidney Cancer Patients with Brain Metastases Treated with Modern Multidisciplinary Approaches

    American Society of Clinical Oncology, 2018

  • Use of Qtc-prolonging Medications Among Patients With Lung Cancer: Implications for Clinical Trials and Standard Clinical Care

    American Society of Clinical Oncology 2018 Annual Meeting, 2018

  • The Enrollment Status of Patients with Brain Metastases in Metastatic Renal Cell Carcinoma: A Query of clinicaltrials.gov

    American Society of Clinical Oncology 2017 Annual Meeting, 2017

  • Anaplastic Lymphoma Kinase Alterations and Inhibition in Lung Cancer

    Seminars in Cancer Biology, 2017

  • Upper Lip Metastasis of Sarcomatoid Carcinoma of the Lung - an Unusual Site of Disease: a Case Report

    Journal of Medical Case Reports, 2017

  • Histologic Transformation of EGFR Mutant Lung Adenocarcinoma Without Wxposure to EGFR Inhibition

    Lung Cancer, 2017

  • Incidence of Brain Metastases in Metastatic Renal Cell Carcinoma in the Era of Targeted Therapies

    ASCO Annual Meeting, 2016

Other Information

Dr. Le is married with one child and a dog. He and his wife enjoy traveling, cooking, and exploring interesting restaurants.